Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients

Human Mutation

Volumn 33, Issue 1, 2012, Pages 95-99

  Thompson, Ella R ^a   Boyle, Samantha E ^a   Johnson, Julie ^b,c   Ryland, Georgina L ^a,d   Sawyer, Sarah ^a   Choong, David Y H ^a   kConFab, ^a   Chenevix Trench, Georgia ^b   Trainer, Alison H ^a   Lindeman, Geoffrey J ^e,f   Mitchell, Gillian ^a   James, Paul A ^a   Campbell, Ian G ^a,g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast cancer; Cancer predisposition; Ovarian cancer; RAD51C

Indexed keywords

GLYCINE; RAD51 PROTEIN; RAD51C PROTEIN; SERINE; UNCLASSIFIED DRUG;

ARTICLE; BASE PAIRING; CANCER FAMILY; CANCER PATIENT; CANCER RISK; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOSITY LOSS; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; INTRON; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; COMORBIDITY; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PEDIGREE; PENETRANCE; RISK FACTORS;

EID: 84857691595     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21625     Document Type: Article

References (19)

1. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA. 2010. RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res 12:404.
2. Baxter SW, Choong DY, Eccles DM, Campbell IG. 2002. Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 11:211-214.
3. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, Campbell IG. 2008. Mutation andmethylation analysis of the chromodomainhelicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10:1253-1258.
4. Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, Li J, Anglesio MS, Campbell IG. 2009. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosome Canc 48:931-942.
5. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. 2002. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609.
6. Jacobs S, Thompson ER, Nannya Y, Yamamoto G, Pillai R, Ogawa S, Bailey DK, Campbell IG. 2007. Genome-wide, high-resolution detection of copy number, loss of heterozygosity, and genotypes from formalin-fixed, paraffin-embedded tumor tissue using microarrays. Cancer Res 67:2544-2551.
7. Jones S, Hruban RH, Kamiyama M, Borges M, ZhangX, ParsonsDW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA,Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. 2009. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217.
8. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K,Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H. 2010. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.4.
9. Moldovan GL, D'Andrea AD. 2009. How the fanconi anemia pathway guards the genome. Annu Rev Genet 43:223-249.
10. Pang Z, Yao L, Zhang J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. 2011. RAD51C germlinemutations inChinesewomenwith familial breast cancer. Breast Cancer Res Treat 129:1019-1020.
11. Pelttari LM,Heikkinen T, ThompsonD,Kallioniemi A, Schleutker J,HolliK, Blomqvist C, Aittomaki K, Butzow R, Nevanlinna H. 2011. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20:3278-3288.
12. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. 2006. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167.
13. Romero A, Perez-Segura P, Tosar A, Garcia-Saenz JA, Diaz-Rubio E, Caldes T, de la Hoya M. 2011. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat 129:939-946.
14. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. 2006. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239-1241.
15. Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Palli D, Ottini L. 2011. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 13:404.
16. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, FreundM, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. 2010. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42:406-409.
17. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ. 2011. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 127:853-859.
18. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. 2011. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353-357.
19. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. 2010. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124:857-861.